The FDA has sent over 2,200 letters urging drug and device makers, as well as researchers, to publish previously unreported clinical trial data to ensure transparency for doctors, patients, and scientific progress.

Historically, roughly 30% of studied clinical trials have not reported results, a gap that can mislead clinical decisions and hinder assessment of a treatment’s value.

The move echoes a 2007 congressional mandate following the Vioxx scandal, highlighting a shift from voluntary to mandatory disclosure.

The FDA says greater transparency enables replication, improves understanding of how medicines work, and can influence treatment choices and healthcare costs.

This effort reflects ongoing federal efforts to enforce and improve compliance with clinical trial reporting requirements.

These letters also serve as reminders to report trial results to a federal database, with the possibility of fines for non-compliance.

Looking ahead, the FDA plans to issue more noncompliance letters, expand enforcement tools, and continue monitoring and penalizing non-reporting to improve trial data transparency.

Public support comes from figures like FDA Commissioner Dr. Marty Makary and advocates including Christopher Morten, Yale Medicine’s Dr. Reshma Ramachandran, and UPenn ethicist Holly Fernandez Lynch, who view data transparency as a scientific and ethical obligation.

Researchers have long argued that inaccessible data hampers replication and undermines confidence in trial findings, affecting clinical and policy decisions.

Internal FDA analysis showed that results were not submitted for nearly 30% of studies likely subject to mandatory reporting.

The letters target entities linked to more than 3,000 registered trials, including some publicly funded studies.

The letters represent an initial step toward stronger enforcement, with potential penalties and plans to use AI and other technology to detect non-compliance.